Vifor Pharma offers £23m to NHS to resolve CMA investigation
The UK’s Competition and Markets Authority (CMA) has received a £23m ($29m) offer from Vifor Pharma for the NHS to …
Post
-
-
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia
Er-Kim has extended its exclusive agreement with Ascendis Pharma, broadening the reach of three endocrinology treatments across multiple countries in …
-
The Innovations Shoring Up Clinical Supply Chain Integrity in the Age of Advanced Therapies
Clinical trials are the testing ground for new therapies. Ensuring the supply chains supporting these therapies remain robust is a …
-
Overcoming the first hurdles: Navigating early phase challenges for biotechs
As smaller, leaner organisations that must utilise resources carefully, biotechs face unique challenges as they enter clinical trials. These challenges …
-
Relation-GSK to drive fibrotic and osteoarthritis developments
Relation has announced two strategic collaborations with GSK, focusing on the discovery and validation of therapeutics that target fibrotic diseases …
-
Relation-GSK to drive fibrotic and osteoarthritis developments
Relation has announced two strategic collaborations with GSK, focusing on the discovery and validation of therapeutics that target fibrotic diseases …
-
Better prevention and treatment options needed for genital herpes, WHO says
A World Health Organization (WHO) director has called for “better prevention and treatment options” after the agency released new estimates …
-
Lilly’s £279m bet aims to boost UK life sciences sector
Leading obesity drugmaker Lilly has announced a £279m ($365.5m) investment in the UK in a major collaboration between the company …
-
ASH 2024: J&J’s Tecvayli shows promise in transplant-eligible NDMM patient
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily …
-
Dr Myles Greenberg becomes president and CEO of InCarda Therapeutics
InCarda Therapeutics has announced the appointment of Dr Myles Greenberg as its new president and CEO. Greenberg brings 25 years of …
-
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
Data from the Phase II ELM-2 trial was presented at the American Society of Hematology (ASH) 2024 Annual Meeting, held …
-
New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III
New Amsterdam Pharma’s obicetrapib has exceeded company expectations in the Phase III BROADWAY trial in adult patients with atherosclerotic cardiovascular …
-
EMA validates Chiesi and Protalix’s dose variation for Fabry disease
The European Medicines Agency (EMA) has validated Chiesi Global Rare Diseases and Protalix BioTherapeutics’ submission to update the dosing regimen …
-
RSV prophylactic market to reach $6.2bn in 8MM by 2030
The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major …
-
Santhera’s DMD therapy Agamree approved for NHS use after new price deal
England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree …
